8/6/2023 0 Comments Knowledge management novamindForward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Included in the underlying index of the Horizons Psychedelic Stock Index ETF Opened a new client care center to maintain its high degree of service amid overwhelming demand for treatments and the planned doubling of clinics by September Novamind will be evaluated as a key research site to conduct Bionomics' phase IIb trial examining BNC210, a potential treatment for post-traumatic stress disorder (PTSD)Īnnounced the expansion and optimization of its clinic in Layton, Utah, which now offers improved treatment rooms to accommodate a higher number of ketamine and Spravato™ treatments Made a strategic investment of AU$965,400 (approximately CAN$942,000) in Bionomics Limited ("Bionomics") (ASX: BNO), which appreciated in value by +55% (unrealized return) as of Fiscal Q3 2021. as a key research site for a phase IIa clinical trial studying MK-1942, an investigational medication for treatment-resistant depression (TRD) as Chief Operating Officer ("COO"), formerly the COO of LifeLabs Inc., Canada's largest diagnostic laboratory services companyĬontracted by Merck & Co. ![]() Scheduled to open four new clinics between July and September 2021, doubling its network to eight total locations and forecasted to increase patient volume to approximately 65,000 clinic visits in 2021, +225% year-over-yearĪppointed Pierre Bou-Mansour, P.Eng. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.įiscal Q3 2021 Business Highlights and Subsequent Eventsīegan trading on the Canadian Securities Exchange (CSE) under the ticker symbol "NM" on January 5 th, 2021 The Company's fiscal year-end is June 30 th. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, reported its fiscal third-quarter results for the three and nine months ended March 31 st, 2021 ("Fiscal Q3 2021"). TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. ![]() Revenue of $1,846,132 for Fiscal Q3 2021, +43% quarter-over-quarterĪnnounced doubling of clinic network by September 2021įorecasting 65,000 clinic visits in 2021, +225% year-over-year
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |